Claims for Patent: 7,601,520

Summary for Patent: 7,601,520

Title:	Method for rapid identification of porcine insulin-like growth factor 2 intron 7 point mutation
Abstract:	A method for rapidly identifying a point mutation in porcine insulin-like-growth factor 2 intron 7 uses published primers to amplify the target DNA fragments by polymerase chain reaction. The DNA fragments are cloned and sequenced for confirmation and method validation. The key positions of the sequence are modified to generate three primers for amplifying different DNA fragments with different genotypes by PCR to avoid additional restriction enzyme digestion. A long primer is used to specifically amplify the lean muscle mass-enhancing allele, a short primer is used to specifically amplify the lean muscle mass-suppressing allele, and the third primer is shared and anneals to the complementary strand. After PCR and electrophoresis, samples with only the 92 bp band are identified as the CC genotype, samples with only the 72 bp band are identified as the GG genotype, and samples with both 92 bp and 72 bp bands are identified as heterozygotes.
Inventor(s):	Chang; Hsiu-Luan (Neipu Township, Pingtung County, TW), Wu; Ming-Che (Neipu Township, Pingtung County, TW), Chu; Chia Te (Neipu Township, Pingtung County, TW)
Assignee:
Application Number:	11/598,659
Patent Claims:	1. A method for rapidly identifying a point mutation in porcine insulin-like-growth factor 2 intron 7 by a mutagenically separated polymerase chain reaction, the method comprising the steps of: (a) extracting a DNA sample from a pig to be identified, the DNA sample including insulin-like-growth factor 2 intron 7; (b) proceeding with a polymerase chain reaction by combining the DNA sample with a solution comprising: a first primer (C primer), wherein said C primer is the DNA sequence: 5'TGTCTGTCTCTCTGTTTCTCTCCCGAGGGTCTGAGACTTCATAC-3' (SEQ ID NO: 3), a second primer (G primer), wherein said G primer is the DNA sequence: 5'-CTCCGAGGGTCTGAGACTTCAGAG-3' (SEQ ID NO: 4), a third primer (K primer), wherein said R primer is the DNA sequence: 5'-CAGGCACATGGCAGGTGCCAATCAATG-3' (SEQ ID NO: 5), and a reaction mixture required for polymerase chain reaction, the first primer amplifying a lean muscle mass-enhancing allele, the second primer amplifying a lean muscle mass-suppressing allele, and the third primer being the third primer is shared by the first primer and the second primer in the PCR reactions; and (c) electrophoresizing a product resulting from step (b) to thereby identify the DNA sample by a band of the DNA sample, in which the DNA sample is identified as muscular genotype when having 92 bp band, the sample is identified as non-muscular genotype when having 72 bp band, and the sample is identified as hetero-genotype when having both 92 bp and 72 bp bands. 2. The method as claimed in claim 1 wherein the DNA sample is of 80-100 ng, and wherein the solution includes 0.8 mM deoxy-nucleotide-triphosphates (dNTP), 0.4-0.6 .mu.M C primer, 0.8-1.2 .mu.M G prima, 0.8-1.2 .mu.M K primer, a reaction mixture containing magnesium ion, 1.times.PCR buffer (75 mM Tris-HCl, pH 9.0, 2 mM MgCl.sub.2, 20 mM (NH.sub.4).sub.2SO.sub.4, and 50 mM KCl of 50 mM), 0.1 mM cresol red (in 20% sucrose), and one unit of Taq DNA polymerase. 3. The method as claimed in claim 1, wherein, in a first cycle of the mutagenically separated polymerase chain reaction, the temperature and time are set as follows: 95.+-.1.degree. C., 110-150 seconds, wherein the temperature and time in next 25 cycles are set as follows: 95.degree. C., 20 seconds; 57.degree. C., 10 seconds; 72.degree. C., 20 seconds, the variation for the time is .+-.5%, and the variation for the temperature is .+-.1.degree. C., and wherein a final reaction is held for 110-150 seconds at 72.+-.1.degree. C. 4. The method as claimed in claim 1 wherein the magnesium ion has a concentration of 2.0 mM and is from magnesium chloride. 5. The method as claimed in claim 2 wherein the C primer has a concentration of 0.50 .mu.M, the C primer has a concentration of 1.0 .mu.M, and the R primer has a concentration of 1.0 .mu.M.

Details for Patent 7,601,520

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26